BioNTech SE

ISIN US09075V1026

WKN A2PSR2

Marktkapitalisatie (in EUR)

19,218 m

Land

Germany

Sector

Healthcare

Dividendrendement

0.00%

|One app for all your investments. Buy crypto, stocks and ETFs easily with Bitpanda. Learn more

Overzicht

Koers

Beschrijving

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Toon meer Toon minder

Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Germany

Grafiek

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR	19,218 m
WPA, EUR	-4.64
KBV	1.0
K/W	159.5
Dividendrendement	0.00%

Income statement (2025)

Omzet, EUR	2,871 m
Netto-inkomen, EUR	-1,137 m
Winstmarge	-39.59%

What ETF is BioNTech SE in?

There are 4 ETFs which contain BioNTech SE. All of these ETFs are listed in the table below. The ETF with the largest weighting of BioNTech SE is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).

ETF	Weging	Investeringsfocus	Fondsgrootte (in m EUR)
iShares STOXX Europe Equity Multifactor UCITS ETF EUR (Dist)	0.04%	Equity Europe Multi-Factor Strategy	180
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0.83%	Equity United States Health Care Biotech	48
Amundi Prime Eurozone UCITS ETF DR (D)	0.16%	Equity Europe	81
Amundi Prime Europe UCITS ETF DR (D)	0.09%	Equity Europe	211

Prestaties

Rendementsoverzicht

YTD	-5,02%
1 maand	-17,28%
3 maanden	-5,02%
6 maanden	-11,29%
1 jaar	-7,74%
3 jaar	-32,81%
5 jaar	-20,23%
Since inception	+519,58%
2025	-24,98%
2024	+13,87%
2023	-33,67%
2022	-33,06%

Maandelijks rendement in een heat map

Risico

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF-rendementen zijn inclusief dividenduitkeringen (indien van toepassing).